The new generation of weight loss injections works in ways that directly affect appetite and digestion. Wegovy contains semaglutide, Mounjaro contains tirzepatide, and Saxenda contains liraglutide. According to MHRA guidance, these are the GLP-1-based products licensed for weight management in the UK. They are prescribed for adults with obesity, or for some adults who are overweight and also have weight-related health problems.

These medicines can be highly effective, but the most frequently reported side effects are gastrointestinal. For semaglutide, the official product information lists nausea, diarrhoea, constipation and vomiting among the most frequently reported adverse reactions. For tirzepatide, the official product information highlights nausea, vomiting and diarrhoea, and warns that these effects can lead to dehydration. MHRA safety communications also note that gastrointestinal side effects with GLP-1 medicines may affect more than 1 in 10 patients.

From a patient’s perspective, that creates a real-world problem. If you are taking Mounjaro or Wegovy and you also notice that dairy-heavy meals, wheat-based foods, rich sauces or highly processed meals make you feel worse, it can be difficult to know whether the issue is:

• an expected medication side effect,

• the dose escalation phase,

• the size or composition of the meal,

• or a separate pattern related to specific foods.

That is where a structured review of food triggers can become useful. In practice, many patients benefit first from a food-and-symptom diary, medication review and nutrition assessment. In selected cases, a food intolerance test may then be considered as part of a broader attempt to understand recurring trigger patterns. This is a practical inference based on the overlap between known medication side effects and food-related symptom patterns.

Weight loss medications currently used in the UK: brand names and example prices

For UK patients researching food intolerance and weight loss medication, the main branded options they are likely to encounter are:

Mounjaro (tirzepatide)

Mounjaro is authorised in the UK for weight management and weight loss in eligible adults, to be used with a reduced-calorie diet and increased physical activity. Example private pricing from Superdrug Online Doctor starts at £176 for the 2.5 mg starter dose, then rises across step-up doses.

Wegovy (semaglutide)

Wegovy is a once-weekly semaglutide injection licensed for weight loss in the UK. Example private pricing from Boots Online Doctor starts at £99.97 for the 0.25 mg starting dose, with higher doses priced higher. Boots also lists 0.5 mg at £119.97, 1 mg at £166.97, 1.7 mg at £192.97, and 2.4 mg at £205.97.

Saxenda (liraglutide)

Saxenda is a daily injection for weight management. Superdrug has listed example prices of £149.99 for 3 pens and £239.99 for 5 pens, although availability can vary.

Orlistat / Xenical / alli

Orlistat is an oral weight loss medicine that reduces how much fat is absorbed from food. Xenical is a branded prescription version of orlistat, while alli is an over-the-counter lower-dose version. Example prices currently listed by Superdrug include Orlistat from £49.99, Xenical from £57.99, and alli 84 capsules at £39.50.

Important note on Ozempic

Patients often search for Ozempic when looking into weight loss treatment. Boots states that Ozempic is not licensed as a weight loss treatment in the UK, even though it contains semaglutide. For weight management, the branded semaglutide product is Wegovy.

Because private prices and stock levels change frequently, any article using prices should label them clearly as example prices at time of writing rather than fixed market rates.

A patient taking weight loss medication may think about food intolerance testing for three main reasons.

First, symptom overlap is common. The symptoms most often discussed by patients starting GLP-1 medicines — nausea, bloating, diarrhoea, constipation, stomach discomfort and occasional headache — are also the kinds of symptoms that make people suspect that certain foods are not suiting them. That does not prove a food intolerance, but it does create a sensible reason to examine patterns carefully.

Second, treatment often changes what and how people eat. Appetite suppression, smaller portions and slower gastric emptying can make some meals feel far heavier than they did before treatment. Rich, fatty or highly processed meals may become less tolerable. With orlistat, the relationship between symptoms and meal composition is even more direct because the medicine works by reducing fat absorption; higher-fat meals are more likely to lead to troublesome gastrointestinal effects.

Third, patients often want to distinguish “expected medication effects” from “specific trigger-food effects.” For example, if a person consistently feels significantly worse after milk-based shakes, creamy coffees, pizza, bread-heavy takeaway meals or high-fat desserts, it may be reasonable to investigate whether a separate food pattern is present rather than assuming all symptoms are caused only by the injection or tablet. This is an inference drawn from how these medicines affect the gut and how meal composition influences tolerability.

Food intolerance symptoms vs weight loss medication side effects

One of the biggest practical challenges is that the symptom lists can look almost identical.

Symptoms commonly reported with GLP-1 weight loss medication

The official information and MHRA safety updates repeatedly highlight nausea, vomiting, diarrhoea, constipation and dehydration risk as important issues with GLP-1 medicines such as Wegovy, Saxenda and Mounjaro. Headache is also described by Boots as a very common side effect of Wegovy and Saxenda.

Symptoms people often attribute to possible food intolerance

Patients commonly look for food intolerance assessment when they have bloating, abdominal discomfort, diarrhoea, fatigue, headaches or feeling unwell after particular foods. On their own, these symptoms are non-specific. They need to be interpreted in context: timing, dose-escalation stage, meal composition, portion size, hydration and any previous history of food-related symptoms all matter.

Why the distinction matters

If a symptom is mostly medication-related, the most useful intervention may be slower dose escalation, dietary modification, hydration support or prescriber review. If symptoms are tightly linked to repeated exposure to specific foods, then a trigger-focused dietary review — sometimes alongside testing — may be more useful. Either way, do not assume all symptoms are food intolerance and do not assume all symptoms are “just the jab.” Persistent, severe or worsening symptoms need clinical review. This is especially important because official sources warn that dehydration and renal complications can occur in severe cases.